Clinical trial NCT02645864: Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Official title: Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Esophageal Squamous Cell Carcinoma
Keywords: Esophageal squamous cell carcinoma
Apatinib
Irinotecan
Lead sponsor: Peking University
Sponsor class: OTHER
Collaborators: name: Jiangsu HengRui Medicine Co., Ltd.
First posted: 2016-01-05
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Esophageal cancer is one of the common malignant tumors. The annual incidence of esophageal squamous cell carcinoma is 260,000 with the mortality of 210,000 in China. Different from that in western countries, esophageal squamous cell carcinoma (ESCC) is still the dominant pathological type in China and account for more than 95% cases in clinic. The prognosis of ESCC is very poor. About 50% of patients have advanced disease at diagnosis with a 5-year survival rate of only 5-7%. Though esophagectomy is standard treatment, disease will relapse in many patients.

For patients with unresectable or recurrent disease, chemotherapy is an important treatment alone or with radiotherapy. Taxane, platinum, and fluoropyrimidine have been reported effective in ESCC and is popularly used in first-line treatment of ESCC. However, there is still no standard 2nd-line treatment for patients who fail in first-line treatment. Both irinotecan and taxane had been studied as 2nd-line treatment for esophageal cancer patients. But there are only a few of ESCC patients involved in those studies.

Except for chemotherapy, targeting treatment is another promising treatment for esophageal cancer. In recent years, antiangiogenic treatment has been proved to be effective and tolerable in many cancers such lung, colorectal, and gastric cancer. Apatinib is an also known as YN968D1, is an orally antiangiogenic agents. Preclinical and clinical data has shown that it is effective in the treatment of a variety of solid tumors including esophageal cancer. And it was approved and launched in China in 2014 as a 3rd-line treatment for patients with advanced gastric cancer.

Therefore, investigators initialize this dose escalation phase I study to explore the safety of irinotecan and apatinib combination treatment in ESCC patients with relapse disease after esophagectomy and failure in 1st-line chemotherapy. Investigators will analyze the maximum tolerated dose (MDT) and dose-limiting toxicity (DLT) in this study.


Eligibility criteria: Inclusion Criteria:

* Patients must have histologically confirmed esophageal squamous cell carcinoma with relapse disease and the primary tumor have been surgically removed.

  * With measurable or evaluable disease defined by RECIST 1.1 criteria by multi-slice spiral CT or MRI scan.
  * - Failed in or disease progressed after fist-line chemotherapy (If failed in perioperative chemotherapy or disease progressed in 24 weeks after perioperative chemotherapy, the perioperative chemotherapy is regard as first-line chemotherapy )
  * - Patients must have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale
  * - Without serious system dysfunction and could tolerate chemotherapy.
  * - With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a neutrophil count of ≥2.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis.
  * - Life expectancy ≥3 months
  * - With normal electrocardiogram results and no history of congestive heart failure.
  * - Without bleeding and thrombosis disease
  * - With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN
  * - Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug
  * - With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors.
  * - With good compliance and agree to accept follow-up of disease progression and adverse events.

Exclusion Criteria:

* Patients who have received irinotecan or apatinib in previous treatment.
* Primary tumor is not resected.
* Uncontrolled hypertension (after treatment with antihypertensive drugs cannot reduced to the normal range: systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg)
* With ≥ grade 2 coronary heart disease, arrhythmia (including corrected QT interval prolongation male \>450 ms, women \>470 ms)
* Cannot take oral tables including uncontrolled vomiting, chronic diarrhea and intestinal obstruction.
* With potential bleeding risk including (1) peptic ulcer and fecal occult blood (++); (2) melena or hematemesis history in last 3 months; (3) fecal occult blood (+) or (+/-) and endoscopy showed ulcer or other diseases with bleeding risk.
* With abnormal coagulation function (INR\>1.5 ULN, APTT\>1.5 ULN),
* With thrombosis or receiving anticoagulant treatment.
* With serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure.
* With brain metastasis of tumor
* Pregnant or lactated women (premenopausal women must give urine pregnancy test before enrollment).

Primary outcomes:
measure: Dose limiting toxicity
timeFrame: From enrollment to 1 months after completion of treatment. Estimated about 3 months.
measure: Maximum tolerance dose
timeFrame: From enrollment to 1 months after completion of treatment. Estimated about 3 months.
Secondary outcomes:
measure: Objective response rate
timeFrame: From enrollment to 3 months after treatment
measure: Progression-free survival
timeFrame: From enrollment to progression of disease. Estimated about 6 months.
measure: Overall survival
timeFrame: From enrollment to death of patients. Estimated about 1 year.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital
state: Beijing
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Xiaodong Zhang
role: PRINCIPAL_INVESTIGATOR
References: